An in vivo Screen for Radiation Sensitizers

辐射敏化剂的体内筛选

• 批准号: 7199477
• 负责人: Tin Tin Su
• 金额: $ 18.14万
• 依托单位: UNIVERSITY OF COLORADO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7199477
• 关键词: Aftercare; Angiogenesis Inhibitors; Apoptosis; Biological Assay; CHES1 gene; Cancer Model; Cancer cell line; Caring; Cell Proliferation; Cells; Cellular biology; Cisplatin; Colorado; Combination Chemotherapy; Developmental Therapeutics Program; Disease; Disease regression; Dose; Drosophila genus; Drosophila melanogaster; Effectiveness; Environment; Gefitinib; Goals; Growth; Growth Factor; Head and Neck Cancer; Head and Neck Neoplasms; Heart; Human; Ionizing radiation; Legal patent; Malignant Neoplasms; Mammals; Mediating; Methods; Microtubules; Modeling; Monitor; Morbidity - disease rate; Mus; National Cancer Institute; Normal tissue morphology; Organ; Outcome; Patients; Pharmaceutical Preparations; Poison; Radiation; Radiation Tolerance; Radiation therapy; Radiation-Sensitizing Agents; Radiosensitization; Receptor Protein-Tyrosine Kinases; Research Personnel; Resistance; Screening procedure; Signal Pathway; Signal Transduction; Standards of Weights and Measures; TP53 gene; Testing; Therapeutic; Time; Tin; Tissues; Toxic effect; Translating; Tumor Suppressor Proteins; Universities; Xenograft procedure; base; cancer cell; cell killing; chemotherapeutic agent; combinatorial; fly; improved; in vivo; in vivo Model; irradiation; mutant; novel; radiation effect; response; small molecule; small molecule libraries; tool; tumor; tumor growth

DESCRIPTION (provided by applicant): Our long-term goal is to rapidly and efficiently identify novel molecules that eradicate head and neck cancers when applied alone and in conjunction with ionizing radiation. The goal for this R21 Exploratory proposal is to establish an efficient, unbiased screening method that will identify radiation sensitizers in a true in vivo setting. Head and neck cancers (HNC) remain extremely difficult to control even with high doses of radiation. Combinations of chemotherapy and radiotherapy have improved local-regional control and patient survival, but at the expense of morbidity. Current focus is on exploring new combinatorial therapies that perturb growth and angiogenic signaling pathways in order to optimize the therapeutic ratio (tumor control/normal tissue toxicity), albeit with an empirical approach. Our goal is to screen from the onset for agents that block critical aspects of cancer cell biology and enhance the effectiveness of radiation in a disease setting such as HNC. Cell-based screens fail to recapitulate the precise tumor environment and may therefore miss useful radiosensitizers. Current in vivo models such as xenografts in mice are costly and cumbersome for rapid screening of new compounds. Radiation responses in Drosophila melanogaster show similarities to radiation responses of tumors, and suggest that Drosophila may be an applicable model. For example, ionizing radiation induces p53-mediated apoptosis, but cell proliferation ensues to compensate and to confer resistance and survival of tumors (in mammals) and organ precursors (in fly). Microtubule poisons that interfere with cell proliferation sensitize Drosophila and human tumors to radiation, while growth factor signaling confers resistance to radiation in both Drosophila and human tumors. The usefulness of a Drosophila model as a rapid screening tool for identifying radiation sensitizers that translate to human cancers will be tested in 2 aims. Aim 1 will be to validate the effect of known radiation sensitizers of human HNC models for their ability to sensitize Drosophila to ionizing radiation. Aim 2 will be to identify, through small molecule libraries, radiosensitizers of Drosophila, and determine their ability to radiosensitize human HNC xenografts. Successful completion of this project would establish a novel, rapid and effective primary screen in vivo for radiosensitizers with potential therapeutic value.

描述（由申请人提供）：我们的长期目标是快速有效地鉴定单独应用和与电离辐射联合应用时根除头颈癌的新型分子。本R21探索性提案的目标是建立一种有效、无偏倚的筛选方法，该方法将在真实的体内环境中识别辐射致敏剂。头颈部癌症（HNC）即使在高剂量辐射下仍然极难控制。联合化疗和放疗改善了局部区域控制和患者生存率，但以牺牲发病率为代价。目前的重点是探索新的组合疗法，干扰生长和血管生成信号通路，以优化治疗比例（肿瘤控制/正常组织毒性），尽管是经验性的方法。我们的目标是从一开始就筛选阻断癌细胞生物学关键方面的药物，并增强放射在HNC等疾病环境中的有效性。基于细胞的筛选不能概括精确的肿瘤环境，因此可能会错过有用的放射增敏剂。目前的体内模型如小鼠异种移植物对于快速筛选新化合物来说是昂贵和繁琐的。果蝇的辐射反应与肿瘤的辐射反应相似，提示果蝇可能是一个适用的模型。例如，电离辐射诱导p53介导的细胞凋亡，但细胞增殖增强以补偿并赋予肿瘤（在哺乳动物中）和器官前体（在苍蝇中）的抗性和存活。干扰细胞增殖的微管毒物使果蝇和人类肿瘤对辐射敏感，而生长因子信号传导赋予果蝇和人类肿瘤对辐射的抗性。果蝇模型作为快速筛选工具用于识别转化为人类癌症的辐射增敏剂的有用性将在2个目标中进行测试。目的1将是验证已知的人HNC模型的辐射增敏剂对果蝇致敏电离辐射的能力的作用。目的2将通过小分子文库鉴定果蝇的放射增敏剂，并确定其对人HNC异种移植物的放射增敏能力。该项目的成功完成将建立一种新型、快速、有效的放射增敏剂体内初步筛选方法。